Core Viewpoint - The price of magnesium trisilicate raw material has surged approximately 30 times due to market monopoly, leading to significant penalties for the involved companies [2][3][5]. Group 1: Market Dynamics - Prior to 2014, the price of magnesium trisilicate was stable at around 17 yuan per kilogram, but after being monopolized, it rose to about 40 yuan per kilogram [2][5]. - The highest market price for magnesium trisilicate reached approximately 30 times the pre-monopoly price during 2018 and 2019 [2][5]. - The market for magnesium trisilicate is currently facing reduced demand due to a shift in consumer health awareness and dietary habits [2]. Group 2: Company Actions and Penalties - Weifang Zhongyuan Pharmaceutical Co., Ltd. was fined a total of 37.65 million yuan for abusing its market dominance in the magnesium trisilicate market from January 2014 to September 2019 [3][5]. - The company controlled 99% of the domestic market share by monopolizing the supply of magnesium trisilicate, significantly impacting the costs for downstream formulation companies [4][5]. - Four other companies were fined 200,000 yuan each for submitting false materials during the investigation [6][8]. Group 3: Regulatory Environment - The State Administration for Market Regulation has emphasized that the investigation into the monopoly is crucial for promoting healthy industry development [2]. - The number of companies with production qualifications for magnesium trisilicate has increased to eight, indicating a potential shift in market dynamics [8].

原料药领域再现垄断新案。 7月18日，国家市场监督管理总局官方通报，潍坊中源医药有限公司在三硅酸镁原料药销售市场中，实 施了不公平高价销售、拒绝交易、附加不合理交易条件等行为，构成滥用市场支配地位。反垄断执法部 门依法责令其停止违法行为，合计罚没金额达3765.22万元。 不仅如此，与潍坊中源有业务往来的四家药企还因不履行配合反垄断调查义务，提交虚假证据等行为， 均被反垄断执法机关处以20万元罚款。 据了解，三硅酸镁是一种主要用于胃药和降压药制剂的重要药品原料，属于我国严格监管的原料药品 类。由于生产和销售均需获得相关许可，市场进入门槛高，竞争格局相对封闭，这一行业特性也使得滥 用行为更易形成。 其余企业中，河北利鑫因环保原因停产，亚宝药业（600351）主要自产自用，三门峡赛诺维虽具备资质 但未实现批量销售。整个市场实际处于单一供应、缺乏竞争的高度集中状态。 同时，由于进口药品需取得国家药监局注册批准，涉案期间无企业获得三硅酸镁原料药进口注册证，也 无法通过国际市场获取替代来源。这一高度封闭格局使得制剂企业对潍坊中源医药形成高度依赖，基本 丧失议价权和替代选择。 售价涨幅达27倍，限制交易方式多样 在取得市 ...

Core Viewpoint - Four pharmaceutical companies were fined 200,000 yuan each for obstructing an antitrust investigation related to magnesium trisilicate raw materials [1][3]. Group 1: Companies Involved - The companies involved in the antitrust case are Shanghai Qingping Pharmaceutical Co., Ltd., Chongqing Mingbo Pharmaceutical Co., Ltd., Weifang Longhai Cheng Pharmaceutical Co., Ltd., and Weifang Jinkaisheng Pharmaceutical Co., Ltd. [1] - These companies had business dealings with Weifang Zhongyuan Pharmaceutical Co., Ltd., which was found to have abused its dominant market position from 2014 to September 2019 [1]. Group 2: Investigation Findings - Weifang Zhongyuan was penalized approximately 37.65 million yuan for unfair pricing, refusal to trade, and imposing unreasonable trading conditions [1]. - During the initial investigation, Shanghai Qingping denied any rebate payments to Weifang Zhongyuan but later admitted to such payments by March 2021 [2]. - Chongqing Mingbo initially denied receiving monopoly profits but later acknowledged that their sales were merely for documentation purposes, returning the sales revenue to Weifang Zhongyuan [2]. - Weifang Jinkaisheng also retracted previous statements made during the investigation, claiming their transactions were not monopolistic [2]. Group 3: Legal Framework - According to the previous Antitrust Law, companies are required to cooperate with antitrust investigations, and failure to do so can result in fines of up to 200,000 yuan for companies [3]. - The actions of the four pharmaceutical companies in submitting false evidence and obstructing the investigation were deemed to waste enforcement resources and hinder normal administrative processes [3].